Semler Scientific stock price target lowered to $86 by Benchmark on acquisition news

Published 23/09/2025, 13:16
Semler Scientific stock price target lowered to $86 by Benchmark on acquisition news

Investing.com - Benchmark lowered its price target on Semler Scientific (NASDAQ:SMLR) to $86.00 from $101.00 on Tuesday while maintaining a Buy rating on the stock. The company, currently trading at $32.06, maintains impressive gross profit margins of 90.84% and trades at a P/E ratio of 8.31, according to InvestingPro data.

The price target adjustment follows Semler Scientific’s announcement that it has agreed to be acquired by Strive, Inc. (NASDAQ:ASST) in an all-stock transaction.

Benchmark analyst Mark Palmer indicated the deal "appears to have rung the opening bell for consolidation in the corporate bitcoin treasury space."

The firm suggested that while the market evaluates the longer-term implications of the transaction, Semler Scientific shares currently represent an investment opportunity.

Semler Scientific is being acquired by Strive, Inc., though specific terms of the all-stock deal were not detailed in the announcement.

In other recent news, Semler Scientific Inc. reported a significant earnings beat for the second quarter of 2025. The company posted earnings per share of $5.04, far exceeding the projected loss of $0.22. Revenue also surpassed expectations, coming in at $8.22 million compared to the forecasted $8.1 million. Additionally, Semler Scientific has entered into a definitive agreement for an all-stock acquisition by Strive Inc., valuing Semler at a 210% premium over its previous closing price. As part of this deal, each Semler common share will be exchanged for 21.05 Class A common shares of Strive. Shareholders of Semler recently approved an increase in shares but rejected a preferred stock proposal. Cantor Fitzgerald reiterated its Overweight rating on Semler Scientific, slightly adjusting the price target to $60.00. These recent developments reflect a period of significant activity for Semler Scientific.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.